Inthelia Therapeutics is developing host-targeted therapies that utilize biomarker-guided approaches to treat severe bloodstream infections caused by bacterial, viral, and fungal pathogens. This method aims to prevent early-stage sepsis and reduce reliance on traditional antimicrobials, addressing the critical issue of antimicrobial resistance.
Funding
Funding not disclosed
Founders
Product
Problem
Sepsis, a life-threatening condition caused by the body's overwhelming response to an infection, leads to millions of deaths worldwide annually. Current treatments primarily rely on antimicrobials, which are becoming less effective due to increasing antimicrobial resistance. There are currently no approved therapies that address the underlying causes of sepsis by modulating the host's response to infection.
Solution
Inthelia Therapeutics is developing host-targeted therapies that aim to treat serious infections and pathogen-induced barrier dysfunctions. Their approach focuses on modulating host factors or pathways that pathogens exploit, enhancing the host’s ability to control or eliminate the infection. By using biomarker-guided precision medicine, Inthelia aims to improve patient outcomes, minimize side effects, and reduce the risk of antimicrobial resistance. This involves leveraging advanced technologies and molecular insights to develop therapies tailored to individual patients suffering from bacterial, fungal, or viral infections.
Target Audience
The primary target audience includes patients suffering from or at risk of developing sepsis and other severe bloodstream infections, as well as healthcare providers seeking alternative or adjunctive therapies to combat antimicrobial resistance.
Features
- Host-targeted therapy approach to modulate the host's response to infection
- Biomarker-guided precision medicine for personalized treatment
- Focus on enhancing the host’s ability to control or eliminate infection
- Potential to reduce the risk of antimicrobial resistance